Summary

Thyrocare Technologies Limited, a leading healthcare diagnostics company, announces their results for the quarter ended June 30, 2025. The company saw a YoY increase of 23% in consolidated revenue, driven by a 25% growth in Pathology and a 6% growth in Radiology. Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase. Consolidated Gross Margin stood at 71%, with reported EBITDA margin at 30%. Consolidated EBITDA grew by 37% YoY, while PAT saw a significant YoY increase of 62%.

Key Highlights

1. 1

   Consolidated revenue saw a YoY increase of 23%

2. 2

   Pathology Business - Franchise revenue grew by 20% YoY, while partnership revenue surged by 36% YoY

3. 3

   Total test volume reached 46.9 million in Q1FY26, reflecting a 15% YoY increase

4. 4

   Consolidated Gross Margin stood at 71%, with reported EBITDA margin at 30%

5. 5

   Consolidated EBITDA grew by 37% YoY, while PAT saw a significant YoY increase of 62%

6. 6

   Opened New Labs in Bhagalpur, Kashmir and Roorkee